The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.
J. C. Byrd
Research Funding - Pharmacyclics
K. A. Blum
Research Funding - Pharmacyclics
J. A. Burger
Research Funding - Pharmacyclics
S. E. Coutre
Research Funding - Pharmacyclics
J. P. Sharman
Honoraria - Pharmacyclics
R. R. Furman
Research Funding - Pharmacyclics
I. W. Flinn
Research Funding - Pharmacyclics
B. W. Grant
Research Funding - Pharmacyclics
D. A. Richards
Research Funding - Pharmacyclics
W. Zhao
Research Funding - Pharmacyclics
N. A. Heerema
Research Funding - Pharmacyclics
A. J. Johnson
Research Funding - Pharmacyclics
R. Izumi
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
A. Hamdy
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
S. M. O'Brien
Research Funding - Pharmacyclics